Tau-targeting Alzheimer’s treatment, HMTM, moving toward regulatory submission based on initial data from TauRx’s LUCIDITY trial
· LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer’s based on published research · Safety profile is favourable and consistent with previous HMTM studies · TauRx will now pursue regulatory submission and coverage for HMTMTauRx Pharmaceuticals Ltd, the global leader in tau-based research in Alzheimer’s, today announced unblinding of initial data from completion of the randomised portion of their pivotal Phase 3 clinical trial, LUCIDITY (NCT03446001). TauRx’s lead investigative oral